ACKB Ackermans & van Haaren NV

Ackermans & van Haaren: Annual results 2020

Ackermans & van Haaren: Annual results 2020

Dear,



  • Ackermans & van Haaren realised a net profit of 229.8 million euros over the full year 2020.
  • Despite the continuing impact of the corona pandemic into the second half of the year, the results of the group made a strong recovery (net profit H2 2020: 173.5 million euros).
  • An increase of the dividend to 2.35 euros per share is proposed to the general meeting of shareholders.



“I am extremely proud of the resilience shown by our 22,331 colleagues throughout the AvH group amidst these uncertain and volatile times caused by the COVID crisis. Over 2020, the AvH group realises a very solid net profit of 230 million euros.

Based upon strong portfolio performances, both Delen Private Bank and Bank J.Van Breda & C° realised very strong inflows of new assets under management that have reached a record level of more than 54 billion euros at year-end 2020. On the back of a strong push towards more renewable energy sources and greening the world economy, DEME increased its order backlog to a record level of more than 4.5 billion euros. 

We remain committed to invest in strengthening our portfolio, and investing in a more sustainable and digital savvy world, as illustrated by our recent investments in OMP, Verdant Bioscience, Medikabazaar and Indigo Diabetes.”

Jan Suykens, CEO - Chairman of the executive committee



You can watch the video message of Jan Suykens, CEO of Ackermans & van Haaren, about the annual results  or read our press release via the link below.

Best regards

Ackermans & van Haaren



Attachment



EN
26/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ackermans & van Haaren NV

 PRESS RELEASE

Ackermans & van Haaren supports MRM Health’s Series B financing round ...

Ackermans & van Haaren supports MRM Health’s Series B financing round of 55 million euros Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren (AvH) supports the Series B financing round totaling 55 million euros of MRM Health, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology. For AvH, this series B financing round involves an additional investment of 3 million euros and brings its total investment in MRM Health to 10.8 million euros and its fully diluted participation to 14.1%. Please find the ...

 PRESS RELEASE

Ackermans & van Haaren soutient le tour de financement de série B de 5...

Ackermans & van Haaren soutient le tour de financement de série B de 55 millions d’euros de MRM Health Cher actionnaire, Monsieur, Madame, Ackermans & van Haaren (AvH) soutient le tour de financement de Série B totalisant 55 millions d’euros de MRM Health, une société biopharmaceutique en phase clinique, pionnière dans les thérapeutiques basées sur le microbiome pour les maladies inflammatoires et l’immuno-oncologie. Pour AvH, ce tour de financement de Série B comprend un investissement supplémentaire de 3 millions d'euros, ce qui porte l'investissement total d'AvH dans MRM Health à 10...

 PRESS RELEASE

Ackermans & van Haaren ondersteunt de serie B-financieringsronde van 5...

Ackermans & van Haaren ondersteunt de serie B-financieringsronde van 55 miljoen euro van MRM Health Geachte aandeelhouder, Geachte mevrouw, geachte heer, Ackermans & van Haaren (AvH) ondersteunt de serie B-financieringsronde van in totaal 55 miljoen euro van MRM Health, een biofarmaceutisch bedrijf in de klinische fase dat pioniert met therapieën op basis van het microbioom voor inflammatoire aandoeningen en immuun-oncologie. Voor AvH omvat deze serie B-financieringsronde een aanvullende investering van 3 miljoen euro, waarmee de totale investering van AvH in MRM Health op 10,8 miljoen...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AEGON & ASR: placing a 6% stake in ASR, happy family. Events Calendar

Hans D’Haese ... (+2)
  • Hans D’Haese
  • Jason Kalamboussis

Ackermans & van Haaren/1H25 postview and model update/HOLD

In this note we update our Sum-of-the-Parts valuation model after the 1H25 results publication and related analyst meeting. This note summarises the key topics from the release and updates our earnings forecasts. Last week's release was a clear illustration of Ackermans & van Haaren's (AvH) successful strategy of focusing on a limited number of assets in different sectors of growth that are jointly creating a regular stream of revenues as the main driver for value creation for the group. We have...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch